Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma

被引：420

作者：

Keating, Gillian M. ^{[1
,2
]}

Santoro, Armando ^{[3
]}

机构：

[1] Wolters Kluwer Hlth Adis, Auckland, New Zealand

[2] Wolters Kluwer Hlth, Conshohocken, PA USA

[3] Ist Clin Humanitas, Dept Med Oncol & Hematol, Milan, Italy

来源：

DRUGS | 2009年 / 69卷 / 02期

关键词：

PHASE-I; RAF/MEK/ERK PATHWAY; BAY-43-9006; COMBINATION; THERAPY; CANCER; MODEL; RISK;

D O I：

10.2165/00003495-200969020-00006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sorafenib (Nexavar (R)) is an orally active multikinase inhibitor that is approved in the EU for the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall survival and delays the time to progression in patients with advanced hepatocellular carcinoma who are not candidates for potentially curative treatment or transarterial chemoembolization. Sorafenib is generally well tolerated in patients with advanced hepatocellular carcinoma. Thus, sorafenib represents an important advance in the treatment of advanced hepatocellular carcinoma and is the new standard of care for this condition.

引用

页码：223 / 240

页数：18

共 51 条

[1] Phase II study of sorafenib in patients with advanced hepatocellular carcinoma [J].

Abou-Alfa, Ghassan K. ;

Schwartz, Lawrence ;

Ricci, Sergio ;

Amadori, Dino ;

Santoro, Armando ;

Figer, Arie ;

De Greve, Jacques ;

Douillard, Jean-Yves ;

Lathia, Chetan ;

Schwartz, Brian ;

Taylor, Ian ;

Moscovici, Marius ;

Saltz, Leonard B. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4293-4300

[2]

ABOUALFA G, 2007, 14 EUR CANC C SEP 23

[3]

ABOUALFA GK, 2008, AM SOC CLIN ONC 44 A

[4] Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature [J].

Adnane, Lila ;

Trail, Pamela A. ;

Taylor, Ian ;

Wilhelm, Scott M. .

REGULATORS AND EFFECTORS OF SMALL GTPASES: RAS FAMILY, 2006, 407 :597-+

[5]

[Anonymous], NCCN CLIN PRACT GUID

[6] Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor [J].

Autier, Julien ;

Escudier, Bernard ;

Wechsler, Janine ;

Spatz, Alain ;

Robert, Caroline .

ARCHIVES OF DERMATOLOGY, 2008, 144 (07) :886-892

[7] Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours [J].

Awada, A ;

Hendlisz, A ;

Gil, T ;

Bartholomeus, S ;

Mano, M ;

de Valeriola, D ;

Strumberg, D ;

Brendel, E ;

Haase, CG ;

Schwartz, B ;

Piccart, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (10) :1855-1861

[8]

*BAYER HEALTHCARE, SOR ADJ TREATM PREV

[9]

BOLONDI L, 2008, 2008 GASTR CANC S JA

[10] Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents [J].

Chaparro, M. ;

Gonzalez Moreno, L. ;

Trapero-Marugan, M. ;

Medina, J. ;

Moreno-Otero, R. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (11-12) :1269-1277

← 1 2 3 4 5 6 →